# MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab

> **NCT04554836** · PHASE2 · COMPLETED · sponsor: **TheraOp** · enrollment: 6 (actual)

## Conditions studied

- Adenocarcinoma of the Colon
- Adenocarcinoma of the Rectum

## Interventions

- **DRUG:** Cetuximab
- **OTHER:** FOLFIRI

## Key facts

- **NCT ID:** NCT04554836
- **Lead sponsor:** TheraOp
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-29
- **Primary completion:** 2024-06-11
- **Final completion:** 2024-06-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04554836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04554836, "MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04554836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*